248 related articles for article (PubMed ID: 12859222)
1. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
Ramsdell JW; Braunstein SN; Stephens JM; Bell CF; Botteman MF; Devine ST
Pharmacoeconomics; 2003; 21(11):819-37. PubMed ID: 12859222
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose.
Ramsdell JW; Grossman JA; Stephens JM; Botteman MF; Arocho R
Am J Manag Care; 1999 Aug; 5(8):1007-24. PubMed ID: 10558125
[TBL] [Abstract][Full Text] [Related]
4. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
Palmer AJ; Roze S; Lammert M; Valentine WJ; Minshall ME; Nicklasson L; Gall MA; Spinas GA
Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S41-51. PubMed ID: 15324515
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
Beale S; Bagust A; Shearer AT; Martin A; Hulme L
Pharmacoeconomics; 2006; 24 Suppl 1():21-34. PubMed ID: 16800160
[TBL] [Abstract][Full Text] [Related]
6. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Tilden DP; Mariz S; O'Bryan-Tear G; Bottomley J; Diamantopoulos A
Pharmacoeconomics; 2007; 25(1):39-54. PubMed ID: 17192117
[TBL] [Abstract][Full Text] [Related]
7. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Culy CR; Jarvis B
Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
[TBL] [Abstract][Full Text] [Related]
8. A comparison of costs for four oral antidiabetic regimens within a managed care population.
Stockl K; Vanderplas AM; Nicklasson L
Manag Care Interface; 2003 Jul; 16(7):31-6. PubMed ID: 12908215
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada.
Coyle D; Palmer AJ; Tam R
Pharmacoeconomics; 2002; 20 Suppl 1():31-42. PubMed ID: 12036382
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
Schwarz B; Gouveia M; Chen J; Nocea G; Jameson K; Cook J; Krishnarajah G; Alemao E; Yin D; Sintonen H
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():43-55. PubMed ID: 18435673
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.
Shearer AT; Bagust A; Liebl A; Schoeffski O; Goertz A
Pharmacoeconomics; 2006; 24 Suppl 1():35-48. PubMed ID: 16800161
[TBL] [Abstract][Full Text] [Related]
12. Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus.
Foster RH; Plosker GL
Pharmacoeconomics; 2000 Sep; 18(3):289-306. PubMed ID: 11147395
[TBL] [Abstract][Full Text] [Related]
13. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
14. An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus.
Simons WR; Hagan MA
Pharmacoeconomics; 2010; 28(9):765-80. PubMed ID: 20799756
[TBL] [Abstract][Full Text] [Related]
15. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
Salas M; Ward A; Caro J
Clin Ther; 2002 Oct; 24(10):1690-705. PubMed ID: 12462297
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analyses of the conversion of patients with non-insulin-dependent diabetes mellitus from glipizide to glyburide and of the accompanying pharmacy follow-up clinic.
Law AV; Pathak DS; Segraves AM; Weinstein CR; Arneson WH
Clin Ther; 1995; 17(5):977-87. PubMed ID: 8595649
[TBL] [Abstract][Full Text] [Related]
17. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.
Dailey GE; Noor MA; Park JS; Bruce S; Fiedorek FT
Am J Med; 2004 Feb; 116(4):223-9. PubMed ID: 14969649
[TBL] [Abstract][Full Text] [Related]
18. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Chakravarty A; Rastogi M; Dhankhar P; Bell KF
J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
[TBL] [Abstract][Full Text] [Related]
19. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C
Clin Ther; 2000 Jan; 22(1):116-27. PubMed ID: 10688395
[TBL] [Abstract][Full Text] [Related]
20. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
